Pfizer (PFE) stock was down on Tuesday after the pharmaceutical company posted its Q3 2025 earnings report. This report started with adjusted earnings per share of 87 cents, compared to Wall Street’s estimate of 63 cents. However, this was down 17.9% year-over-year from $1.06 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of $16.5 billion. Despite the beat, the company’s revenue still declined 7% year-over-year from $17.7 billion. The company’s revenue drop comes from a 55% drop in Paxlovid sales due to lower COVID-19 infections and a 20% drop in Comirnaty sales due to narrower vaccine guidance.
Pfizer stock was down 0.77% in pre-market trading on Tuesday, following a slight gain yesterday. The stock has fallen 2.97% year-to-date and 11.9% over the past 12 months.
Pfizer Guidance
Pfizer updated its 2025 guidance in its most recent earnings report. The company narrowed and increased its adjusted EPS guidance to between $3 and $3.15, compared to its prior estimate of $2.90 to $3.10. It also reaffirmed its revenue outlook of $61 billion to $64 billion for the year. It noted this guidance includes the impact of tariffs. For comparison, Wall Street expects the company to report adjusted EPS of $3.04 alongside revenue of $62.83 billion during this period.
Is Pfizer Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Pfizer is Hold, based on four Buy, 12 Hold, and a single Sell rating over the past three months. With that comes an average PFE stock price target of $28.60, representing a potential 15.98% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
